作为GLP-1受体激动剂的替代品的内源性葡萄糖样 (GLP) -1:这可以工作,以及如何?
Mark M Smits1,2,3, Jens J Holst1,4
1Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Diabetes/metabolism research and reviews
|July 24, 2023
概括
类似葡萄糖 (GLP) - 1受体激动剂提供心血管和减肥的好处. 本综述探讨刺激内源GLP-1释放作为一种潜在的治疗策略,并将其与现有的激动剂进行比较.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 类似葡萄糖 (GLP) - 1受体激活剂在治疗2型糖尿病和肥胖症方面显示出显著的益处.
- 这些激动剂降低心血管风险,促进患者减肥.
研究的目的:
- 为了比较GLP-1受体激动剂和内源GLP-1之间的作用机制.
- 评估刺激内源GLP-1释放作为治疗方法的潜力.
- 讨论内源GLP-1调节的临床相关性.
主要方法:
- 关于GLP-1受体激动剂和内源GLP-1的现有文献的审查.
- 药理作用和临床结果的比较分析.
- 讨论针对GLP-1通路的潜在治疗策略.
主要成果:
- GLP-1受体激动剂和内源GLP-1表现出不同的作用路径,尽管具有相似的临床效果.
- 目前GLP-1受体激动剂的局限性需要探索替代策略.
- 当内源GLP-1得到适当的刺激时,可能会带来临床上显著的益处.
结论:
- 刺激内源GLP-1释放是GLP-1受体激动剂的一个有希望的替代品或辅助剂.
- 了解内源性和外源性GLP-1作用之间的细微差别对于治疗开发至关重要.
- 对内源GLP-1调节的进一步研究可能会为代谢和心血管疾病开启新的治疗范式.
更多相关视频
相关概念视频
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Oral Hypoglycemic Agents: Glinides
188
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
188
Hypoglycemia and Glucagon
302
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
302
Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Hormones Regulating Blood Glucose
3.5K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.5K


